RadyoBogaz | UCLA’s Dr. Antoni Ribas joins Vial’s CRO advisory board | PR Newswire| SAN FRANCISCO — A pioneer in the field of immuno-oncology, Dr. Antoni Ribas, has recently joined the Oncology Scientific Advisory Board at Vial. Along with the other members of the board, Dr. Ribas will provide guidance to Vial regarding the introduction of their forthcoming oncology CRO.
The objective of The Vial CRO is to rethink clinical trials by delivering trials that are both faster and of a higher quality than ever before. This will be accomplished by leveraging a robust technology platform and focusing on operational excellence. The goal of Vial is to become a trusted partner to biotech companies. Vial has developed an enrollment strategy that provides a trouble-free web-based site start-up, a dedicated recruiting team, and EMR filtering capabilities in order to transfer potential subjects to a centralized pre-screen team. This was done in order to ensure that recruitment deadlines are reached. In addition, the knowledgeable CRAs at Vial have access to the power of real-time data through eSource, which enables them to drive error-free processes and offer high-quality data.
“I have devoted my career to the development of innovative Oncology therapies and I joined the Vial CRO advisory board to support the development of clinical trial infrastructure that enables scientists in advancing the field. I look forward to working with fellow Oncology investigators on the Vial SAB board to help Vial implement innovative approaches to Oncology clinical trials.” said Dr. Ribas on joining the board.
Antoni Ribas, MD, Ph.D. serves as Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC), and the Chair of the Melanoma Committee at SWOG. Dr. Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene-engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors, and nanoparticle-siRNA. Dr. Ribas started his academic career at the University of Barcelona before pursuing postdoctoral research and fellowships at UCLA.
See the full release here.